XBiotech Inc. (NASDAQ:XBIT) saw strong trading volume on Monday . 1,823,997 shares traded hands during trading, an increase of 115% from the previous session’s volume of 846,991 shares.The stock last traded at $19.90 and had previously closed at $15.78.

Several analysts recently weighed in on the company. Noble Financial restated a “buy” rating and set a $24.00 price target on shares of XBiotech in a report on Thursday, May 19th. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Tuesday, May 24th.

The firm’s 50 day moving average is $16.87 and its 200-day moving average is $11.69. The company’s market cap is $625.97 million.

In other XBiotech news, Director W Thorpe Mckenzie acquired 20,000 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were bought at an average cost of $13.96 per share, with a total value of $279,200.00. Following the completion of the acquisition, the director now owns 3,898,600 shares in the company, valued at $54,424,456. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.